AI Summary
In a Phase 3 trial called AtTEnd, researchers found that Atezolizumab combined with chemotherapy improved progression-free survival in patients with advanced or recurrent endometrial cancer, especially in those with dMMR tumors. This suggests a potential benefit of adding Atezolizumab to standard chemotherapy as a first-line treatment for this specific subgroup of patients.
Atezolizumab plus chemotherapy increased progression-free survival in patients with advanced or recurrent endometrial carcinoma, particularly in those with dMMR carcinomas, suggesting the addition of atezolizumab to standard chemotherapy as first-line treatment in this specific subgroup.